Mini Review Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/rheumatology.1.004
Rheumatoid arthritis – assessments and treatment recommendations
Timm Rüter1, Jens Gert Kuipers1.*
- 1Department of Rheumatology, Rotes Kreuz Krankenhaus Bremen, Bremen, Germany
Corresponding Author
Jens Gert Kuipers, Kuipers.J@roteskreuzkrankenhaus.de
Received Date: June 25, 2020
Accepted Date: July 27, 2020
Rüter T, Kuipers JG. Rheumatoid arthritis – assessments and treatment recommendations. Curr Rheumatol Res 2020. 1(1): 9-14.
Copyright: © 2020 Rüter T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Rheumatoid arthritis is a chronic autoimmune inflammatory disease causing joint pain, swelling, destruction and premature death. This minireview summarizes the clinically relevant information on classification, assessment of disease activity and functional status and gives a synopsis of the current ACR and EULAR recommendations for the management and treatment of RA.
Recommended Articles
T helper cells: Top targets for Systemic Lupus Erythematosus treatment?
In the original research article, Parisa R et al. demonstrated that the induction of lupus-like autoimmune syndrome in BALB/c Mice caused disturbance in splenic T cell subpopulations. This study also elucidated those other mechanisms, apart from disturbance in T cells balance, may be responsible for the development of the disease’s symptoms [1].
Acute chikungunya fever followed by systemic lupus erythematosus
Chikungunya fever (CHIKF) is a viral disease caused by the chikungunya virus (CHIKV), a single-stranded positive-sense RNA virus in the Alphavirus genus of the Togaviridae family. Like many other arboviral diseases, it is transmitted by mosquito vectors, primarily Aedes aegypti and Aedes albopictus.
Multiple RNA-binding proteins associated with long interspersed element-1 encoded ORF1p are targeted by the autoimmune response in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a relatively common autoimmune disease characterized by the presence of autoantibodies against nucleic acids and proteins that associate with them, such as the ORF1p protein encoded by the long interspersed element-1 (LINE-1 or L1). Because well-known lupus autoantigens like RO60 associate with ORF1p in macromolecular assemblies, together with many other RNA-binding proteins, we tested whether these other proteins are also recognized by IgG autoantibodies in SLE patients. By ELISAs and immunoblots, we detected autoantibodies in the serum of SLE patients recognizing proteins encoded by LARP7, MOV10, ZCCHC3, MEPCE, YARS2, RPL18A, RPL27A, and H2BC17 (p<0.05), but not CORO1B, DDX6, PABPC1, and PABPC4, and were mostly absent or low in healthy controls.
Membrane complement regulatory protein CD59 in systemic lupus erythematosus and rheumatoid arthritis
Complement proteins constitute a proinflammatory system of the innate immunity which bridges with the adaptive immunity. It comprises of a group of serum zymogens, complement regulatory proteins (Cregs) and receptors.
Dual targeting of plasma cells and B-cells to treat systemic lupus erythematosus
Autoimmune disorders, such as systemic lupus erythematosus, are associated with significant morbidity that is often ultimately refractory to current treatment modalities. To target the role of autoantibodies in disease pathogenesis, biologics have been designed for selective targeting of B-cells.